ArticleTargeted oncology2017

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Anke E M van Erp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.